Data Landlords
These companies own the critical information that powers modern business and innovation. Like digital landlords, they lease access to invaluable data streams that others simply can't replicate, creating powerful competitive advantages and consistent revenue streams.
Your Basket's Financial Footprint
Structured data for the 'Data Landlords' basket market capitalisation and investor key takeaways.
- Large-cap dominance suggests generally lower volatility and closer tracking of broad markets, offering comparatively steadier performance and reduced risk.
- Use this basket as a core, long-term holding for portfolio stability rather than a speculative growth allocation.
- Expect steady, long-term appreciation; it tends to prioritise reliable earnings over potential short-term explosive gains.
EFX: $28.14B
TRU: $15.77B
FICO: $37.59B
- Other
About This Group of Stocks
Our Expert Thinking
These companies control vast, proprietary datasets that other businesses need to function. By owning and monetizing unique information assets like credit histories, market data, and specialized analytics, they've built 'data moats' that competitors can't easily cross—positioning them for stable growth and strong profit margins.
What You Need to Know
Unlike tech companies that simply use data to support other products, these firms directly monetize information as their primary business. This creates a high-margin, scalable model with recurring revenue. Many have established themselves as industry standards, giving them significant pricing power and market stability.
Why These Stocks
The explosion in artificial intelligence development has dramatically increased demand for high-quality, large-scale datasets. These companies own exactly what AI needs to function, potentially increasing their strategic value. We've selected firms with the deepest data moats and clearest monetization strategies in this growing space.
Why You'll Want to Watch These Stocks
The Ultimate Competitive Moat
These companies own data that's impossible or prohibitively expensive for others to replicate. Their information monopolies create lasting advantages that translate to consistent revenue streams and strong margins.
AI's Secret Ingredient
As artificial intelligence development accelerates, the companies that control quality training data are positioned to benefit enormously. These firms sit on the exact resources that tomorrow's AI technologies desperately need.
Subscription-Based Profit Machines
Many of these data landlords operate on recurring revenue models, leasing access to their information through subscriptions. This creates predictable cash flow and reduces vulnerability to market volatility.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Global Infrastructure Partners: UAE Exposure Risks
The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.
UAE Infrastructure Global Suppliers Breakdown
As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.